69 Afatinib versus gefitinib as first-line treatment for...

Lung Cancer 2016 / 01 Vol. 91

69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7

O'Byrne, K.J., Park, K., Tan, E., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C., Mok, T., Kim, M., Massey, D., Zazulina, V., Paz-Ares, L.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
91
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/S0169-5002(16)30086-1
Date:
January, 2016
File:
PDF, 58 KB
english, 2016
Conversion to is in progress
Conversion to is failed